We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 1BMY market cap is 109.5B. The company's latest EPS is USD 3.9568 and P/E is 14.57.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 26.15B | 42.52B | 46.39B | 46.16B | 45.01B |
| Operating Income | 5.8B | 3.12B | 7.87B | 7.24B | 6.91B |
| Net Income | 3.44B | -9.02B | 6.99B | 6.33B | 8.03B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 129.94B | 118.48B | 109.31B | 96.82B | 95.16B |
| Total Liabilities | 78.25B | 80.6B | 73.31B | 65.7B | 65.67B |
| Total Equity | 51.7B | 37.88B | 36.01B | 31.12B | 29.49B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 8.07B | 14.05B | 16.21B | 13.07B | 13.86B |
| Investing | -9.77B | -10.86B | -538M | -1.06B | -2.3B |
| Financing | 7.62B | -1.15B | -16.22B | -16.96B | -9.42B |
| Market Cap | 109.5B |
| Price to Earnings Ratio | 14.57 |
| Price to Sales Ratio | 2.6 |
| Price to Cash Ratio | 10.2 |
| Price to Book Ratio | 3.97 |
| Dividend Yield | 4.82% |
| Shares Outstanding | 2.03B |
| Average Volume (1 week) | 63 |
| Average Volume (1 Month) | 67 |
| 52 Week Change | 14.87% |
| 52 Week High | 56.81 |
| 52 Week Low | 36.00 |
| Spread (Intraday) | 0.19 (0.35%) |
| Company Name | Bristol Myers Squibb |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.bms.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
